What Is Opus Genetics, Inc. (IRD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Opus Genetics, Inc.'s intrinsic value is estimated at $1.21, suggesting the stock is overvalued at its current price of $3.48. With 8 out of 9 models flagging downside (-65.1% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +9.2% (fair value: $3.80), while Dynamic NAV is the most conservative at -97.1% ($0.10). The spread between these extremes — +106.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About IRD?
9 of 13 models are currently active for IRD. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates IRD's intrinsic value at $1.06, implying -69.5% downside from the current price. See which stocks rank higher →
How Does IRD Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IRD ranks #161 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Opus Genetics, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is IRD a Value Trap?
CirclFi's Value Trap algorithm assigns IRD a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Opus Genetics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Opus Genetics, Inc.'s fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +106.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IRD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IRD's 9 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad